Cancer, Gynecological

Uterine Fibroids Adenomyosis Endometrial polyps Gynecologic cancers Alteration of endometrium, changes in uterine contractility Alteration of endometrium, changes in uterine contractility Alteration of endometrium Various dysplastic alterations of endometrium, uterus, cervix... 

Cancer antigen 125 (CA-125). The normal level is less than 35 units/mL (35 kU/L). This test is associated with a lack of specificity. CA-125 can be elevated in a number of other states, such as different phases of the menstrual cycle, endometriosis, and non-gynecologic cancers. It is important to rule out other cancers associated with the abdominal cavity. 

Israel VP, Garcia AA, Roman L, et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000 78 143. 

BRCAl and BRCA2 are frequently mutated in a variety of human cancers. Breast cancer is the most common malignancy in women. A total of more than a million women will be diagnosed with breast cancer worldwide with more than 400,000 deaths annually. The germ line mutations of BRCAl/2 are associated with hereditary breast cancer which account for 5-7% of all breast cancer cases (12, 13). Ovarian cancer is the leading cause of death from gynecological cancer with more than 140,000 deaths annually worldwide. The germ line and somatic BRCAl/2 mutations have been reported to occur in approximately 10% of ovarian cancer patients (14, 15). BRCAl/2 mutations have also been shown to occur frequently in Ashkenazi Jewish families with pancreatic cancer (16). 

Radiosensitizing Abilities of the Taxanes Application in the Clinic Nonsmall-Cell Lung Cancer Small-Cell Lung Cancer Brain Tumors Genitourinary Cancers Gynecological Cancers Breast... 

Safe SH, Zacharewski T. 1997. Organochlorinc exposure and risk for breast cancer. In Aldaz CM, Gould MN, Me Lachlan J, et al, eds. Etiology of breast and gynecological cancers. New York, NY Wiley-Liss Inc, 133-145. 

Verloop J, Rookus MA, van Leeuwen FE. Prevalence of gynecologic cancer in women exposed to diethylstilbestrol in utero. N Engl J Med 2000 342(24) 1838-9. 

Umland EM, Rinaldi C, Parks SM, Boyce EG. The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann Pharmacother 1999 33(12) 1315—28. 

Rezk YA, Balulad SS, Keller RS, Bennett JA. 2006. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin Study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194 e23-e26. 

Yavuz L, Eroglu F, Ozsoy M. The efficacy of intravenous versus epidural tramadol with patient-controlled analgesia (PCA) in gynecologic cancer pain. EurJ Gynaecol Oncol. 2004 25 215-218. 

Riisbro R, Stephens RW, Brunner N, Christensen IJ, Nielsen HJ, Heilmann L, et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 2001 82(3) 523-531. 

---